TalkMed Company profile
About TalkMed Group Ltd
TalkMed Group Limited is a Singapore-based investment holding company. The Company’s Oncology services segment is engaged in the provision of oncology services to Parkway Cancer Centre, a division of Parkway Hospitals Singapore Pte. Ltd., Thu Cuc International General Hospital in Hanoi, Vietnam and Hong Kong Integrated Oncology Centre Holdings Limited. The Company has expanded its oncology services to China. Its Stem cell related products and services segment is engaged in the provision of services related to processing, culturing and storage of stem cells through its subsidiary, Stem Med Pte. Ltd. (Stem Med) to Parkway Cancer Centre, a division of Parkway Hospitals Singapore Pte. Ltd., StemCord Pte Ltd, the non-controlling shareholder of Stem Med and other individual customers. The Cellular and gene therapy related products and services segment is engaged in the provision of goods and services related to cellular and gene therapy through its subsidiary, CellVec Pte. Ltd.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, TalkMed Group Ltd revenues decreased 2% to SP$60.7M. Net income increased 10% to SP$25.1M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Net income reflects Impairment loss decrease from SP$3.4M (expense) to SP$0K, Cost of share-based payments to employee decrease of 76% to SP$512K (expense).
Latest shares articles
![](https://img.capital.com/imgs/articles/384x2000x0/1350x880_-HP-_Newsquawk-light_1.png)
![Lloyds share price forecast: An attractive dividend stock?](https://img.capital.com/imgs/articles/384x2000x0/Hero-image-bank_1.png)
![Exterior of Infosys headquarters](https://img.capital.com/imgs/articles/384x2000x0/shutterstock_2035197281_0_0.jpg)
![Tesla logo atop of a Tesla Dealership illuminated at night.](https://img.capital.com/imgs/articles/384x2000x0/shutterstock_1494516293_0.jpg)